AYLA

Noble Financial analyst Robert LeBoyer reiterated a Buy rating on Ayala Pharmaceuticals (AYLA – Research Report) today and set a price target of $12.00. The company's shares closed last Monday at $2.11, close to its 52-week low of $1.97. According to TipRanks.com, LeBoyer is a 4-star analyst with an average return of 7.9% and a 29.5% success rate. LeBoyer covers the Healthcare sector, focusing on stocks such as Lineage Cell Therapeutics, Onconova Therapeutics, and PDS Biotechnology. The word on The Street in general, suggests a Strong Buy analyst consensus rating for Ayala Pharmaceuticals with a $13.00 average price target.
https://www.tipranks.com/news/blurbs/noble-financial-reaffirms-their-buy-rating-on-ayala-pharmaceuticals-ayla?utm_source=advfn.com&utm_medium=referral